ADM Plans Green Production for USP-Grade Propylene Glycol
Archers Daniel Midland Company (Decatur, IL) is bringing on line a new propylene glycol plant in Decatur, Illinois, in the fourth quarter of 2009.
Archer Daniels Midland Company (ADM, Decatur, IL) is bringing on line a new propylene glycol plant in Decatur, Illinois, in the fourth quarter of 2009. The plant will produce industrial-grade and United States Pharmacopeia (USP)-grade propylene glycol, which may be used as an excipient in pharmaceutical products.
The plant’s capacity is 100,000 metric tons, which represents approximately 12% of the US capacity for propylene glycol for 2010, according to the company. The Decatur plant is ADM’s first propylene glycol plant, and the company says it is the first worldwide propylene glycol plant that manufactures a grade of USP-grade propylene glycol from renewable sources.
ADM’s renewable propylene glycol is derived from soybeans or rapeseeds. The company processes soybeans or rapeseeds through a crushing, dehulling process, conditioning, and flaking operation into a crude vegetable oil. This vegetable oil is further processed into degummed or refined oil. The vegetable oil is processed through a transesterfication process into crude biodiesel and crude glycerin. The crude glycerin is further processed through several evaporation and distillation steps into a refined, kosher, USP-grade glycerin. This glycerin is either sold into the market or reacted through ADM’s hydrogenolysis process into propylene glycol. The propylene glycol is further distilled into an industrial grade or a USP grade of propylene glycol.
In addition to manufacturing propylene glycol from glycerin, ADM has the capability to manufacture propylene glycol via sorbitol. Sorbitol is also a renewable-based feedstock that ADM produces through its corn milling process.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
